Approved For Marketing EXPANDED_ACCESS NCT04040660

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (NEXT)

Sponsor: MediWound Ltd

Interventions NexoBrid

Updated 6 times since 2019 Last updated: Aug 28, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04040660, this observational or N/A phase trial focuses on Thermal Burn and remains ongoing. Sponsored by MediWound Ltd, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Approved For Marketing
Sep 2024 — Sep 2025 [monthly]

Approved For Marketing

Status: Available → Approved For Marketing
Jul 2024 — Sep 2024 [monthly]

Available
Jan 2021 — Jul 2024 [monthly]

Available
Feb 2020 — Jan 2021 [monthly]

Available

▶ Show 1 earlier version

Sep 2019 — Feb 2020 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediWound Ltd

Data source: MediWound Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Allentown, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Bridgeport, United States , Charleston, United States , Columbus, United States , Dallas, United States , Gainesville, United States and 16 more locations